Australian researchers have demonstrated that the use of a new, less toxic drug combination after stem cell transplants for ...

Debiopharm ( a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to ...

VANFLYTA (quizartinib) has been approved by Health Canada for use in combination with standard cytarabine and anthracycline ...

Acute myelogenous leukemia, or AML, remains one of the most aggressive blood cancers. Each year, around 44,000 people in the ...

Gene therapy is revolutionizing how they're treated, and the Fred Hutch Cancer Center in Seattle is at the center of it all. ...

A new cancer treatment discovered by the University of California, San Diego Sanford Stem Cell Institute (SSCI) and developed ...

Acute myeloid leukemia (AML) is an aggressive blood cancer characterized by the accumulation of immature myeloid cells. Current treatments often fail to achieve durable remission, underscoring the ...

Panelists explain that KMT2A-rearranged acute myeloid leukemia (AML) is an aggressive, molecularly distinct leukemia subtype marked by menin-dependent transcriptional dysregulation, poor response to ...

Discover the inspiring stories of Axola May and Lee-Ann Scholtz, two young South Africans battling blood cancer. Learn how ...

The HSCT program services are available to local and international patients, with over 50 children awaiting transplantation ...